Invivyd granted six newly hired, non-executive employees options to purchase an aggregate of 255,000 common shares on September 1, 2026. The awards were issued as material inducements to employment under Nasdaq Listing Rule 5635(c)(4) and the Invivyd, Inc. 2026 Inducement Plan. The options have an exercise price of $0.8799 per share, matching the stock’s closing price on the grant date, a 10-year term and four-year vesting schedule. Twenty-five percent vests on the first anniversary of each employee’s start date, with the balance vesting in equal monthly installments thereafter, subject to continuous service. Invivyd is developing antibody-based protection against serious viral infectious diseases, beginning with SARS-CoV-2, and received U.S. FDA emergency use authorization for a monoclonal antibody candidate in March 2024.